Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature
Office of the Revisor of Statutes

HF 3026

1st Engrossment - 91st Legislature (2019 - 2020) Posted on 04/28/2020 02:11pm

KEY: stricken = removed, old language.
underscored = added, new language.
Version List Authors and Status
Pdf Rtf

Current Version - 1st Engrossment

Line numbers 1.1 1.2 1.3 1.4
1.5 1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 2.1 2.2 2.3 2.4

A bill for an act
 relating to human services; exempting treatment from approved clinical trials from
coverage; amending Minnesota Statutes 2018, section 256B.0625, subdivision 64.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2018, section 256B.0625, subdivision 64, is amended to
read:


Subd. 64.

Investigational drugs, biological products, deleted text begin anddeleted text end devicesnew text begin , and clinical
trialsnew text end .

deleted text begin (a)deleted text end Medical assistance and the early periodic screening, diagnosis, and treatment
(EPSDT) program do not cover new text begin the new text end costs new text begin of any services that are new text end incidental to, associated
with, or resulting from the use of investigational drugs, biological products, or devices as
defined in section 151.375new text begin or any other treatment that is part of an approved clinical trial
as defined in section 62Q.526. Participation of an enrollee in an approved clinical trial does
not preclude coverage of medically necessary services covered under this chapter that are
not related to the approved clinical trialnew text end .

deleted text begin (b) Notwithstanding paragraph (a), stiripentol may be covered by the EPSDT program
if all the following conditions are met:
 deleted text end

deleted text begin (1) the use of stiripentol is determined to be medically necessary;
 deleted text end

deleted text begin (2) the enrollee has a documented diagnosis of Dravet syndrome, regardless of whether
an SCN1A genetic mutation is found, or the enrollee is a child with malignant migrating
partial epilepsy in infancy due to an SCN2A genetic mutation;
 deleted text end

deleted text begin (3) all other available covered prescription medications that are medically necessary for
the enrollee have been tried without successful outcomes; and
 deleted text end

deleted text begin (4) the United States Food and Drug Administration has approved the treating physician's
individual patient investigational new drug application (IND) for the use of stiripentol for
treatment.
 deleted text end

deleted text begin This paragraph does not apply to MinnesotaCare coverage under chapter 256L.
 deleted text end